- At least 6 patients in each cohort in Phase II (HRD known prior to enrollment or detected during pre-enrollment screening) must also have provided informed consent for and be willing to undergo a tumour and skin biopsy prior to treatment (after registration) and after cycle 2 day 8. Note: During accrual to this portion of the study, it may be necessary to restrict accrual to patients who are suitable for, and have consented to, tumour and skin biopsies.